These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2839891)

  • 21. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
    Ofosu FA
    Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low molecular weight heparins--state-of-the-art and unsolved issues.
    Breddin HK
    Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S17-9. PubMed ID: 8180324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High and low molecular weight heparins do not modify red blood cell aggregability in vitro.
    Martínez M; Vaya A; López-Camacho C; Coll-Sangrona E; Mira Y; Aznar J
    Clin Hemorheol Microcirc; 2000; 23(1):67-70. PubMed ID: 11214715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Low-molecular-weight heparins].
    Rocha E; Páramo JA; Sarrá J
    Med Clin (Barc); 1993 Apr; 100(16):620-7. PubMed ID: 8388527
    [No Abstract]   [Full Text] [Related]  

  • 25. Binding of heparin fractions to von Willebrand factor: effect of molecular weight and affinity for antithrombin III.
    Baruch D; Ajzenberg N; Denis C; Legendre P; Lormeau JC; Meyer D
    Thromb Haemost; 1994 Jan; 71(1):141-6. PubMed ID: 8165633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological activities of heparins obtained from different tissues: enrichment of heparin fractions with high lipoprotein lipase, antihemolytic and anticoagulant activities by molecular sieving and antithrombin III affinity chromatography.
    Bianchini P; Osima B; Parma B; Nader HB; Dietrich CP
    J Pharmacol Exp Ther; 1982 Feb; 220(2):406-10. PubMed ID: 7057400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-anticoagulant effects of unfractionated and low-molecular weight heparins.
    Walenga JM
    Clin Adv Hematol Oncol; 2007 Oct; 5(10):759-60. PubMed ID: 17998892
    [No Abstract]   [Full Text] [Related]  

  • 28. [Comparative analysis of unfractionated and low molecular weight heparins on the polymerization process of fibrin].
    Barkagan ZS; Solomina TA
    Biull Eksp Biol Med; 1997 Sep; 124(9):346-7. PubMed ID: 9445624
    [No Abstract]   [Full Text] [Related]  

  • 29. High and low anticoagulant activity heparins. Preparation in large scale and degree of complexation with antithrombin III.
    Takahashi HK; Nader HB; Dietrich CP
    Arzneimittelforschung; 1985; 35(11):1620-3. PubMed ID: 4091864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fractionation and structural features of two heparin families with high antithrombotic, antilipemic and anticoagulant activities.
    Bianchini P; Osima B; Parma B; Nader HB; Dietrich CP; Casu B; Torri G
    Arzneimittelforschung; 1985; 35(8):1215-9. PubMed ID: 4074437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use.
    Bick RL; Frenkel EP; Walenga J; Fareed J; Hoppensteadt DA
    Hematol Oncol Clin North Am; 2005 Feb; 19(1):1-51, v. PubMed ID: 15639107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of human osteoblast growth by unfractionated heparin and by low molecular weight heparins in vitro.
    Kock HJ; Handschin AE
    Thromb Haemost; 2002 Aug; 88(2):361-2. PubMed ID: 12195714
    [No Abstract]   [Full Text] [Related]  

  • 33. [Thrombin].
    Camici M; Sagripanti A; Di Mitri R
    Minerva Med; 2000; 91(5-6):105-12. PubMed ID: 11084844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemistry and pharmacology of low molecular weight heparin.
    Rosenberg RD
    Semin Hematol; 1997 Oct; 34(4 Suppl 4):2-8. PubMed ID: 9399404
    [No Abstract]   [Full Text] [Related]  

  • 35. Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
    Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Covalent complexes between low molecular weight heparin fragments and antithrombin III - inhibition kinetics and turnover parameters.
    Hoylaerts M; Holmer E; de Mol M; Collen D
    Thromb Haemost; 1983 Apr; 49(2):109-15. PubMed ID: 6868006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of thrombin inactivation by immobilized heparin.
    Byun Y; Jacobs HA; Kim SW
    J Biomed Mater Res; 1996 Apr; 30(4):423-7. PubMed ID: 8847350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biochemical and functional study of antithrombin III in newborn infants.
    McDonald MM; Hathaway WE; Reeve EB; Leonard BD
    Thromb Haemost; 1982 Feb; 47(1):56-8. PubMed ID: 7071806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The first component of the human complement system recognizes the active fraction of heparin.
    Calabrese GC; Recondo MM; Fernández de Recondo ME; Recondo EF
    Cell Mol Biol (Noisy-le-grand); 1997 Mar; 43(2):237-42. PubMed ID: 9130607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new chronometric assay to determine plasma antifactor Xa activity which is insensitive to the antithrombin activity of low molecular weight heparins.
    Dignac M; Gabaig AM; Cambus JP; Boneu B
    Nouv Rev Fr Hematol (1978); 1994; 35(6):545-9. PubMed ID: 8152901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.